Evidence map›Paper›PMID 36810936›Full record

ArticleThoracic cancer2023

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report.

Satoshi Ikeo, Naoaki Yasuda, Yuki Sakai, Yasuyuki Hayashi, Akihiko Sokai, Toshiyuki Iwata, Takashi Nishimura

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Satoshi IkeoDepartment of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.ORCID 0000-0002-0959-4779
Naoaki YasudaDepartment of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
Yuki SakaiDepartment of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
Yasuyuki HayashiDepartment of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
Akihiko SokaiDepartment of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
Toshiyuki IwataDepartment of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
Takashi NishimuraDepartment of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
Kyoto Katsura Hospital · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal epithelial transition factor receptor (MET) tyrosine kinase inhibitors (MET-TKIs) have been approved for the treatment of non-small cell lung cancers with MET exon 14 skipping mutations. Transient asymptomatic pulmonary opacities (TAPOs) associated with epidermal growth factor receptor (EGFR)-TKIs have been reported. Here, we report a case wherein ground-glass opacities (GGOs) appeared during the course of treatment with tepotinib, a MET-TKI, but spontaneously resolved with drug withdrawal, after which treatment was resumed with a reduced dose. Although there have been no reports of TAPOs with MET-TKIs, the clinical and imaging findings of this case were consistent with TAPOs. For TAPOs occurring because of MET-TKI, the drug can be continued under careful observation even if GGOs appear.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsExonsHumansMutationProtein Kinase InhibitorsProto-Oncogene Proteins c-metProtein Kinase InhibitorsProto-Oncogene Proteins c-metlung cancerMET exon 14 skippingtepotinibtransient asymptomatic pulmonary opacities

Identifiers

PMID36810936
PMCPMC10067352
OpenAlexW4321497566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.